Over the past two years, China has become one of the leading locations for high-precision and scalable diagnostic procedures. Advances are focused on ultrasensitive liquid biopsy, CRISPR-based rapid tests, and AI-powered automation in clinical laboratories. These developments are being accelerated by national programs such as “Healthy China 2030” and regulatory adjustments by the National Medical Products Administration (NMPA ).

Liquid biopsy and ultrasensitive NGS diagnostics

Chinese research groups have contributed significantly to the clinical validation of liquid biopsy technologies (ctDNA, CTCs, exosomes). A review in Biomedicines (2026) summarizes new sequencing and error suppression technologies that enable early cancer detection with high sensitivity. Another study in Science China (2025) describes multi-cancer early detection approaches based on cfDNA, cfRNA, proteins and metabolites in combination with AI algorithms.

The Chinese liquid biopsy market is growing from USD 704 million (2025) to a projected USD 1,915 million by 2035 (CAGR 10.5%). Partnerships such as Pillar Biosciences with AstraZeneca (December 2025) have significantly expanded access to putty-based NGS liquid biopsy panels in Chinese clinics.

CRISPR-based diagnostics

Chinese teams have optimized CRISPR/Cas systems (especially Cas12a and Cas13) for highly specific, amplification-free or one-step point-of-care tests. A review in Frontiers in Cellular and Infection Microbiology (February 2026) analyzes mechanistic principles and clinical applications in infectious diseases. Further work in Analytical Chemistry (2025) and Trends in Analytical Chemistry (2026) shows advances in single nucleotide detection (SNV detection) using chemically modified gRNAs and dual fluorescence signals. In peer-reviewed studies, these methods achieve high sensitivity at very low target concentrations.

AI and automation in clinical laboratories

AI systems are increasingly being integrated into routine diagnostics. An international expert survey by the IFCC Committee on AI in Laboratory Medicine (published in 2026 in Clinical Chemistry and Laboratory Medicine) shows that Chinese laboratories are leading the way in implementing AI-powered image and data analysis. Multicenter studies demonstrate significant improvements in diagnostic accuracy and turnaround times in hematology, clinical chemistry, and microbiology. Automated laboratory systems and robot-assisted processes are already standard in large diagnostic centers.

In summary, China has significantly accelerated the translation of innovative laboratory technologies into clinical routine through targeted investments and regulatory adjustments. Advances are primarily in scalability, cost efficiency and the integration of molecular diagnostics into oncology and infectiology.

Vlad Georgescu analysed.

Further information:

• Liquid Biopsy in Early Screening of Cancers: Emerging Technologies and New Prospects – PubMed
• Liquid biopsies for the diagnosis of early-stage gastric cancer: A 5-year systematic review – ScienceDirect
• Frontiers | CRISPR-based diagnostics for infectious diseases: mechanisms, advancements and clinical transformation prospects
• Engineered CRISPR/Cas Ribonucleoproteins for Enhanced Biosensing and Bioimaging | Analytical Chemistry
• Implementation of AI systems in the clinical laboratory (Clinical Chemistry and Laboratory Medicine, 2026)
• Recent advances in CRISPR-based single-nucleotide fidelity diagnostics | Communications Medicine

Editor: X-Press Journalistenbüro GbR

Gender Notice. The personal designations used in this text always refer equally to female, male and diverse persons. Double/triple naming and gendered designations are used for better readability. ected.